1133122-99-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2,3-difluorobenzenesulphonamide is used as a key intermediate in the synthesis of various pharmaceuticals for its unique reactivity and properties. The presence of fluorine atoms enhances the compound's ability to participate in reactions, leading to the creation of new drug molecules with improved efficacy and selectivity.
Used in Organic Chemistry:
In the field of organic chemistry, 2,3-difluorobenzenesulphonamide is used as a versatile building block for the construction of complex organic molecules. Its unique chemical properties allow for a wide range of reactions, making it a valuable component in the synthesis of specialty chemicals and advanced materials.
Used in Antibacterial and Antimicrobial Agents:
2,3-difluorobenzenesulphonamide is used as an active ingredient in the development of novel antibacterial and antimicrobial agents. Its inherent antimicrobial properties contribute to the creation of new treatments for bacterial infections, addressing the growing concern of antibiotic resistance.
Used in Research and Development:
In the realm of pharmaceutical research and development, 2,3-difluorobenzenesulphonamide serves as a valuable tool for exploring new chemical spaces and discovering potential drug candidates. Its unique properties and reactivity enable researchers to investigate new avenues in drug design and development, ultimately contributing to the advancement of medicine.

Upstream product

• 210532-24-4 2,3-difluorobenzenesulphonyl chloride 
• 4519-40-8 2,3-difluoroanilline 

Downstream Products

• 1204573-14-7 2-cyclopropylamino-3-fluorobenzenesulphonamide 

Relevant academic research and scientific papers

Thermodynamic characterization of new positive allosteric modulators binding to the glutamate receptor A2 ligand-binding domain: Combining experimental and computational methods unravels differences in driving forces

Positive allosteric modulation of the ionotropic glutamate receptor GluA2 presents a potential treatment of cognitive disorders, for example, Alzheimer's disease. In the present study, we describe the synthesis, pharmacology, and thermodynamic studies of a series of monofluoro-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides. Measurements of ligand binding by isothermal titration calorimetry (ITC) showed similar binding affinities for the modulator series at the GluA2 LBD but differences in the thermodynamic driving forces. Binding of 5c (7-F) and 6 (no-F) is enthalpy driven, and 5a (5-F) and 5b (6-F) are entropy driven. For 5d (8-F), both quantities were equal in size. Thermodynamic integration (TI) and one-step perturbation (OSP) were used to calculate the relative binding affinity of the modulators. The OSP calculations had a higher predictive power than those from TI, and combined with the shorter total simulation time, we found the OSP method to be more effective for this setup. Furthermore, from the molecular dynamics simulations, we extracted the enthalpies and entropies, and along with the ITC data, this suggested that the differences in binding free energies are largely explained by the direct ligand-surrounding enthalpies. Furthermore, we used the OSP setup to predict binding affinities for a series of polysubstituted fluorine compounds and monosubstituted methyl compounds and used these predictions to characterize the modulator binding pocket for this scaffold of positive allosteric modulators.